Back to News
Market Impact: 0.2
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP reminded investors of a shareholder class-action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The notice represents a legal and reputational risk for Capricor, though the excerpt provides no allegations, damages, class period, or operational impact details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
CAPR-0.85
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- Flavio Bolsonaro faces corruption probe weeks before Brazil election
- Super Micro Computer Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Super Micro Computer, Inc.
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
- Federal budget deficit reaches $2T in first 11 months of fiscal year 2026, CBO reports